Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 248

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part II, Item 2
Chunk 248
---
ant.31.2 Rule 13a-14(a)/15d-14(a) Certifications of Atabak Mokari, Chief Financial Officer of the registrant.32.1 18 U.S.C. Section 1350 Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.32.2 18 U.S.C. Section 1350 Certifications of Atabak Mokari, Chief Financial Officer of the registrant.101 The following materials from the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2025 and December 31, 2024, (ii) Unaudited Condensed Consolidated Statements of Income for the three and nine month periods ended September 30, 2025 and 2024, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three and nine month periods ended September 30, 2025 and 2024, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine month periods ended September 30, 2025 and 2024, (v) Unaudited Condensed Consolidated Statement of Stockholders’ Equity and (vi) Notes to Unaudited Condensed Consolidated Financial Statements.104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 CORCEPT THERAPEUTICS INCORPORATED  Date: November 4, 2025/s/ Joseph K. Belanoff Joseph K. Belanoff, M.D.Chief Executive Officer  Date: November 4, 2025/s/Atabak Mokari Atabak Mokari Chief Financial OfficerDate:November 4, 2025/s/Joseph D. LyonJoseph D. LyonChief Accounting & Technology Officer

45